Cancer drug combo reveals new targets for cell energy

Credibility

Interest

Share:2 min read

Key Takeaway

Researchers found a new drug (AcTor) that, when paired with an existing cancer drug (ixazomib), forces cancer cells to lose their energy and die — a finding that highlights how targeting cell “powerhouses” and protein cleanup systems can be very powerful.

What They Found

Scientists created AcTor, a first-of-its-kind small molecule that blocks part of the TSC complex and turns on a cell-growth pathway called mTOR. By itself, AcTor changes how cells make and use energy, but when paired with the cancer drug ixazomib (which blocks the cell’s protein cleanup system called the proteasome), the combination caused cancer cells to lose mitochondrial function and die. The combo raised harmful reactive oxygen species (ROS) and caused apoptosis, which is programmed cell death — like a controlled shutdown. This effect was seen in many types of acute myeloid leukemia cells, including cells from patients and cells that had become resistant to other cancer drugs. In mice with human leukemia, the drug pair lowered cancer burden, reduced leukemia stem cells, worked even after relapse, and helped in tumors that had mutations in the TP53 gene (a gene often linked to cancer).

Who Should Care and Why

People with MS and their caregivers should know about this study because it focuses on basic cell systems—energy production (mitochondria), protein cleanup (proteasome), and the mTOR pathway—that are also important in nerve health and immune cells. Think of mitochondria as batteries for cells and the proteasome as the cell’s trash truck; problems with batteries and trash removal affect many illnesses, not just cancer. While this work is about leukemia, it may guide future research into treatments that protect or adjust these systems in nerve cells, which could one day matter for MS symptom management or slowing damage. Caregivers and patients may find it useful to follow research on cell energy and protein cleanup, because new therapies for different diseases sometimes inspire ideas for MS treatments. Clinicians and researchers working on MS might study similar drug targets, but this specific drug combination is not tested or approved for MS yet.

Important Considerations

This study was done in lab cells and in mice with human leukemia, not in people with MS, so we don’t know if the findings apply to MS patients. AcTor is a TSC2 inhibitor that the authors say should not be used alone in cancer, and it has not been tested for safety or benefit in humans for MS. Any connection between this cancer research and MS treatments is speculative until clinical studies directly test safety and effectiveness in people with MS.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research Treatment Updates Clinical Trials

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Molecular cancer often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News